New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Vienna, Austria, Thursday 15 April: Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH – the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage. GS-9450, a potent inhibitor of caspases-8, -9 and -1, the intra-cellular proteins that initiate programmed cell death (or cell suicide, also known as apoptosis) in damaged cells, is a potential new treatment option for patients with NASH – a disease characterised by fat build-up in liver cells with subsequent inflammation resulting in accumulation of scar tissue (fibrosis), cirrhosis and eventual liver failure.
Professor Fabio Marra of the EASL scientific committee commented: "It is encouraging to see that GS-9450-associated reduction of apoptosis and cell damage seen in animal models has translated to a significant patient population, and seems to be consistent with a good tolerability profile in patients from a variety of countries. Further studies are needed to evaluate the action of this therapy on histology and to confirm the drug's efficacy and safety in larger patient populations."
In this double-blind, parallel-group study, patients (n=124, principally male, mean age 45 years, with Body Mass Index (BMI) of >30kg/m2) with biopsy-proven NASH were randomised to receive 1, 5, 10 or 40mg GS-9450 or placebo once daily for 4 weeks. After 4 weeks on treatment, patients in the 40mg treatment group experienced the greatest reduction in ALT and AST levels.
At week four, linear regression of ALT versus GS-9450 dose was highly significant (p<0.0001) with 35% achieving ALT levels within the normal range (7-56 U/L ) compared to 0% at study baseline, and 48% achieving normal levels of AST (5-40 U/L1) compared to 20% at baseline. Placebo treatment showed no meaningful change for ALT or AST.
Additionally, the on-treatment measure of cytokeratin-18 caspase cleavage fragments (proteins that act as markers for liver cell death) declined in the 10 and 40mg dose groups (median baseline and week four values respectively were 540 and 445 U/L in the 10mg group and 562 and 386 U/L in the 40mg group), although no dose-related response was seen.
- Hepatitis C treatment reduces the virus but liver damage continuesTue, 9 Dec 2008, 11:01:02 EST
- What's the role of Kupffer cells in non-alcoholic steatohepatitis?Mon, 3 Nov 2008, 9:21:35 EST
- New data emerges on liver transplant survival ratesWed, 25 Nov 2009, 0:30:16 EST
- Encouraging findings suggest new avenues for treating liver disease in overweight AmericansMon, 18 Oct 2010, 10:04:22 EDT
- Metobolomics uncovers key indicators of nonalcoholic fatty liver diseaseTue, 24 Nov 2009, 6:43:29 EST
Articles on the same topic
- High dose UDCA therapy does not improve overall liver histology in obesity related hepatitisFri, 16 Apr 2010, 10:38:16 EDT
- G1 HCV patients who achieve an early viral response can be successfully treated within 6 monthsFri, 16 Apr 2010, 10:38:14 EDT
- New insights into treatment options for patients suffering from severe alcoholic hepatitisFri, 16 Apr 2010, 10:38:00 EDT
- New studies help establish potential of artificial liver support devicesFri, 16 Apr 2010, 10:37:59 EDT
- Genetic signatures provide new direction in liver cancerFri, 16 Apr 2010, 9:29:15 EDT
- Clinical advancesFri, 16 Apr 2010, 8:19:32 EDT
- Study shows potential benefit of dark chocolate for liver disease patientsThu, 15 Apr 2010, 11:31:12 EDT
- Innovation in scienceThu, 15 Apr 2010, 9:42:53 EDT
- Genetic signatures provide new direction in liver cancerfrom Science BlogFri, 16 Apr 2010, 11:07:53 EDT
- New insights into treatment options for patients suffering from severe alcoholic hepatitisfrom Science BlogFri, 16 Apr 2010, 11:07:50 EDT
- New insights into treatment options for patients suffering from severe alcoholic hepatitisfrom PhysorgFri, 16 Apr 2010, 10:50:07 EDT
- New studies help establish potential of artificial liver support devicesfrom Science BlogFri, 16 Apr 2010, 10:29:06 EDT
- Genetic signatures provide new direction in liver cancerfrom PhysorgFri, 16 Apr 2010, 10:29:00 EDT
- Clinical advancesfrom Science BlogFri, 16 Apr 2010, 8:14:34 EDT
- Study shows potential benefit of dark chocolate for liver disease patientsfrom PhysorgThu, 15 Apr 2010, 15:18:42 EDT
- Potential benefit of dark chocolate for liver disease patientsfrom Science DailyThu, 15 Apr 2010, 12:09:40 EDT
- Innovation in sciencefrom Science BlogThu, 15 Apr 2010, 9:35:36 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Printing artificial bone
- Artificial sweetener a potential treatment for Parkinson's disease
- Testosterone improves verbal learning and memory in postmenopausal women
- Submarine springs reveal how coral reefs respond to ocean acidification
- Jet stream changes cause climatically exceptional Greenland Ice Sheet melt
- Even with defects, graphene is strongest material in the world
- Detection of the cosmic gamma ray horizon: Measures all the light in the universe since the Big Bang
- Genetic engineering alters mosquitoes' sense of smell
- Allosaurus fed more like a falcon than a crocodile, new study finds
- 'Popcorn' particle pathways promise better lithium-ion batteries